Regeneron Pharma (REGN) PT Lowered to $785 at Cantor Fitzgerald on Disappointing Trial Results
Cantor Fitzgerald analyst Carter Gould lowered the price target on Regeneron ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)